In recent years, and particularly following the success of anti-PD-1/PD-L1 (programmed cell death protein 1/programmed death ligand 1) checkpoint immunotherapy, there has been a realisation that a tumour is a complex mixture of different cell types that interact to promote tumour progression, and this has generated significant interest in developing therapies that target the tumour microenvironment (TME) [1]. Here, CD274 is linked to neoplasm.